The study followed patients at five leading academic centres and found a significant decrease (p <0.01) in pain scores after targeted radiofrequency ablation (t-RFA) with the Star (DFINE) tumour ablation system.
Unintended non-target delivery of embolic agents into any of the various hepaticoentric arteries that course from an intrahepatic artery to implant into an extra hepatic organ such as the stomach or small intestine can result in serious complications, especially gastrointestinal ulcerations, particularly with Y-90 microspheres. Now, temporary antireflux devices are available that appear to provide both adequate retrograde and antegrade protection against nontarget delivery of cytotoxic agents,
Over the years, we have seen a rapid development of tools, tricks and techniques that enable ablation of tumours located in regions that are in close proximity to thermally sensitive organs or structures, writes Nishita Kothary (Stanford University, USA).
Preliminary observations from the trial were presented at the Global Embolization Symposium and Technologies US (GEST US meeting, 1–4 May, San Francisco, USA) and show increased tumour penetration with the Surefire system.
Interventional radiology techniques are widely performed and useful in liver metastases from neuroendocrine tumours, but the level of scientific proof is paradoxically low, especially when considering that these techniques are used in patients with cancer, write Maxime Ronot and Valérie Vilgrain
Surefire Medical has announced that the COSY clinical trial (Coiling vs. Surefire infusion system in Y90) showed significant reductions in fluoroscopy time, procedure time, radiation dose and contrast dose when using the Surefire Infusion System without coiling.
The largest study of its kind to date shows that minimally invasive radioembolization may slow metastatic disease progression in liver when no other treatment options remain, according to research being presented at the Society of Interventional Radiology’s 39th Annual Scientific Meeting (22–27 March, San Diego, USA).
The outcomes from our study on the efficacy and safety of percutaneous cryoablation, published recently in CardioVascular and Interventional Radiology (CVIR), are the result of the most rigorous investigation on the subject to-date. These exceptional numbers, however, are a double-edged sword. On one hand, they approach those of the gold standard, on the other, we must prove they are widely reproducible, writes Christos Georgiades
Investigators from the MORE (Metastatic colorectal cancer liver metastases outcomes after radioembolization) study have released new findings at the American Society of Clinical Oncology’s 2014 Gastrointestinal Cancers Symposium confirming that standard laboratory tests are a valuable tool for predicting patient outcomes prior to Selective Internal Radiation Therapy (SIRT).
Cryoablation kills tumours and provides pain relief to patients whose cancer has spread to the bone and soft tissue, suggests research being presented at the 6th annual Symposium on Clinical Interventional Oncology (CIO), in collaboration with the International Symposium on Endovascular Therapy (ISET).
A prospective single-arm, five-year study has found that CT-guided percutaneous cryoablation for renal cell carcinoma offers very high efficacy, approaching that of the gold standard, surgery. Cryoablation also has a more favourable safety profile.
Future Medicine Ltd has announced the launch of a new journal, Hepatic Oncology. This new title focuses specifically on the specialism of hepatic cancer, including both primary and secondary malignancies.
The Netherlands presidency of the European Council and representatives of the European Parliament have reached a political agreement on two draft regulations for medical devices. The new regulations ...
Scott Trerotola, Stanley Baum professor of Radiology and chief, Vascular and Interventional Radiology, University of Pennsylvania Medical Center, Philadelphia, USA, discussed how competition improves ...